Plain-English summary
Court affirms enablement requires detailed disclosure for broad antibody patents
The Court unanimously held that two Amgen patent applications claiming all antibodies that bind and block PCSK9 are not enabled under the Patent Act because they do not teach how to make and use the full scope claimed. The Federal Circuit’s ruling that enablement is a legal question was affirmed and applied to find the patents invalid for lack of enablement.
Why this matters
This decision restricts how broadly pharmaceutical and biotech companies can claim classes of biological molecules (like antibodies) without detailed instructions. Patents that claim wide groups of molecules must include adequate disclosure so others skilled in the field can make and use the entire claimed group. That affects incentives for investment, how companies draft patents, and what competitors can lawfully make.
Who may feel it
- Biotech and pharmaceutical companies that patent antibodies and other biological molecules
- Patent applicants and patent attorneys who draft claims and disclosures
- Generic and biosimilar manufacturers and competitors
- Investors and consumers interested in drug development and competition